Lilly Alimta For Lung Cancer “Reasonably Likely” To Improve Survival

Lilly's Alimta is "reasonably likely" to improve survival in non-small cell lung cancer patients despite not meeting the primary endpoint of overall survival in pivotal trials, labeling says